McCormac Paul 4
4 · Lexeo Therapeutics, Inc. · Filed Nov 9, 2023
Insider Transaction Report
Form 4
McCormac Paul
Chief Technical Officer
Transactions
- Conversion
Series B convertible preferred stock
2023-11-07−29,061→ 0 total→ Common Stock (3,191 underlying) - Conversion
Common Stock
2023-11-07+3,191→ 17,349 total
Footnotes (1)
- [F1]Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.